Business context and reporting period
Entity mismatch: Although the request identifies Moonlake Immunotherapeutics, the supplied Form 10-Q is for Helix Acquisition Corp., a Cayman Islands blank-check company. It covers the quarter ended March 31, 2021; the statements are unaudited. Helix was formed to pursue a business combination and had not commenced operating activities.
Financial results and position
- Revenue: No operating revenue. The company reported $17,815 of interest income from trust investments.
- Expenses and profit: Formation and operating costs were $94,106; net loss was $76,291. Loss per non-redeemable ordinary share was $0.03. Profit margins are not meaningful for this pre-combination entity.
- Cash flow: Operating cash used was $107,795 and financing cash used was $58,063, primarily repayment of a related-party note. Cash decreased $165,858 to $1,170,066.
- Liquidity and assets: Working capital was approximately $1.4 million. Total assets were $116.5 million, including $115.0 million in the trust account, primarily U.S. Treasury securities.
- Debt and liabilities: No related-party note or working-capital loans were outstanding at quarter-end. Total liabilities were $4.1 million, including a $4.025 million deferred underwriting fee payable only if a business combination closes.
Changes versus prior period
Compared with December 31, 2020, cash outside the trust account declined from $1.336 million to $1.170 million, and total liabilities declined from $4.150 million to $4.085 million, including repayment of the $58,063 related-party note. Trust assets rose slightly, from $115.015 million to $115.033 million. The filing does not provide a prior-year quarter income statement comparison, so year-over-year operating trends cannot be assessed.
Outlook, risks and unusual items
- Management expected available working capital and borrowing capacity to fund needs through the earlier of a business combination or one year from the filing. Helix had until October 22, 2022—24 months after its IPO—to complete a combination; otherwise, it generally must redeem public shares and liquidate.
- The company expected ongoing costs to identify and evaluate a target and said it might need additional financing if expenses exceed estimates or redemptions are significant. Sponsor or insiders could, but were not obligated to, provide working-capital loans.
- COVID-19 could adversely affect the company or its target search; the specific effect was not determinable. The filing also warns that negative interest rates could reduce trust value and public-share redemption proceeds.
- The sponsor was owed a $10,000 monthly administrative-services fee; $30,000 was incurred in the quarter. The deferred underwriting fee is contingent on completing a business combination.
- Management reported effective disclosure controls and no material changes in internal control. It reported no legal proceedings and no material changes to previously disclosed risk factors.
Most important facts to verify
- Confirm the intended issuer: this filing is for Helix Acquisition Corp., not Moonlake Immunotherapeutics.
- Verify the trust balance, redemption terms and October 22, 2022 business-combination deadline.
- Assess whether the $1.17 million of unrestricted cash is sufficient for the target search and transaction costs, and whether additional financing may be needed.
- Check the period label in MD&A: it refers to cash used in the “three months ending March 31, 2020,” while the reported figures and financial statements are for the quarter ended March 31, 2021.
- Review sponsor-related obligations and the $4.025 million deferred underwriting fee, payable only upon a completed business combination.